Transanal total mesorectal excision versus laparoscopic total mesorectal excision for mid and low rectal cancer (COLOR III): short-term outcomes of an international, multicentre, phase 3, randomised, controlled, non-inferiority trial

Esophagus Diseases

Thoracoscopic versus open oesophagectomy for patients with oesophageal cancer (JCOG1409 MONET): a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial

Lancet Gastroenterol Hepatol

Takeuchi H, Machida R, Ando M, Tsubosa Y, Kikuchi H, Kawakubo H, Noma K, Ueno M, Tsushima T, Bamba T, Fujita T, Hamai Y, Kakishita T, Daiko H, Koyanagi K, Matsuda S, Kato K, Sasaki K, Kita R, Kitagawa Y, JCOG1409 investigators

doi: 10.1016/S2468-1253(25)00207-9

Gastrointestinal Cancer

Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial

Lancet Oncol

Sebag-Montefiore D, Adams R, Gollins S, Samuel LM, Glynne-Jones R, Harte R, West N, Quirke P, Sun Myint A, Bach S, Parsons P, Dhadda AS, Brown N, Brown G, Harrison M, Maggs R, Begum R, Chang E, Hackshaw A, Lopes A, ARISTOTLE Trial Management Group and Investigators

doi: 10.1016/S1470-2045(26)00132-4

Gastrointestinal Cancer

Five-Year Outcomes of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy for Locally Advanced Rectal Cancer: Updated Results of the STELLAR Trial

J Clin Oncol

Tang Y, Zhou HT, Xu TZ, Li N, Jiang LM, Jiang J, Lu NN, Li S, Chen SL, Ma HY, Cai Y, Li YH, Zhu Y, He MY, Wang X, Liu K, Zhang HY, Wang J, Zhao T, Li GF, Yang JL, Zhang K, Wang WL, Xiao WW, Chi Y, Yang L, Zhou AP, Zou SM, Fang H, Wang SL, Zhang HZ, Wang XS, Wei LC, Liu SX, Gao YH, Li YX, Hu C, Jin J

doi: 10.1200/JCO-25-02387

Gastritis

Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial

Lancet Gastroenterol Hepatol

Gonsalves NP, Dellon ES, Kliewer KL, Shoda T, Yearout R, Aceves SS, Arva NC, Besse JA, Caldwell JM, Chehade M, Coleman A, Collins MH, Anvari S, Falk GW, Gupta SK, Hiremath G, Katzka DA, Khoury P, Leung J, Menard-Katcher C, Menard-Katcher P, Peterson KA, Pletneva MA, Spergel AKR, Spergel JM, Vaysman T, Wechsler JB, Wright BL, Yang GY, Zhang X, Zhou M, Bansal A, Raphael BP, Radwan A, Maloney J, Martin A, Deniz Y, Furuta GT, Martin LJ, Rothenberg ME, Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) Investigators

doi: 10.1016/S2468-1253(26)00116-0

Gallbladder and Biliary Diseases

Elafibranor in primary biliary cholangitis: two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE® phase III trial

J Hepatol

Kowdley KV, Bowlus CL, Levy C, Akarca U, Alvares-da-Silva MR, Andreone P, Arrese M, Corpechot C, Elbeshbeshy H, Francque S, Heneghan MA, Invernizzi P, Jacobson IM, Jones D, Kremer AE, Kruger FC, Kugelmas M, Lawitz E, Mayo MJ, Shiffman ML, Sonderup M, Swain MG, Valera JM, Vierling JM, Villagrasa A, Villamil A, Antunes N, Raskino C, Sleiman M, Cranham V, Miller B, Schattenberg JM

doi: 10.1016/j.jhep.2026.08.016

Gastrointestinal Cancer

Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial

Lancet

Sun HC, Zhu XD, Shen F, Song TQ, Bai XL, Zeng YY, Chen MS, Huang ZY, Cai JQ, Gao J, Kuang M, Li DY, Xing BC, Li XC, Wen TF, Peng T, Wang YD, Liu LX, Huang C, Shi YH, Huang XW, Wang K, Gao Q, Zhou J, Fan J

doi: 10.1016/S0140-6736(26)01252-3

Gastrointestinal Cancer

Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial

Lancet

Hecht JR, Park YS, Tabernero J, Lee MA, Lee S, Virgili AC, Van den Eynde M, Fontana E, Fakih M, Asghari G, So J, Stein A, Dubreuil O, Bodnar L, He CS, Wang G, Smith R, Eng C, Saeed A, STELLAR-303 study investigators

doi: 10.1016/S0140-6736(25)02025-2

Gallbladder and Biliary Diseases

Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Lancet Gastroenterol Hepatol

Hirschfield GM, Bowlus CL, Jones DEJ, Kremer AE, Mayo MJ, Tanaka A, Andreone P, Jia J, Jin Q, Macías-Rodríguez RU, Cobitz AR, Currie BM, Gorey C, Lazic I, Podmore D, Ribeiro A, Shannon JB, Swift B, McLaughlin MM, Levy C, GLISTEN Study Group

doi: 10.1016/S2468-1253(25)00192-X

Further Publications

A randomized, double-blind, phase 3, non-inferiority trial of pradefovir mesylate versus tenofovir disoproxil fumarate in chinese patients with chronic hepatitis B

Hepatology

Yanhang G, Xinrui W, Zhongfeng W, Fei K, Lvfeng Y, Weidong L, Jia S, Yunsong Y, Weifeng Z, Jinlin H, Shuangsuo D, Shufen Y, Guoxin H, Bei Z, Hui C, Suling C, Xiaoping D, Xie X, Liu Z, Zhang Z, Song X, Mao Q, Jiang Y, Meng C, Ge F, Su Z, Mao Q, Bai Y, Yu L, Tan Y, Fan H, Jiao Z, Fu X, Hong L, Xu Y, Yan X, Liu J, Gao Y, Gao H, Chen G, Hongguang Q, Cui H, Wu S, Lu X, Liu Z, Liu F, Li X, Sun S, Ding G, Han T, Wang X, Zhao W, Xiang M, Chen X, He W, Lu S, Zeng W, Hu Q, Zhang D, Jin W, Wang D, Wang Y, Zhang C, Wen X, Gao Z, Lv L, Yu K, Li G, Zhang G, Wu G, Niu J

doi: 10.1097/HEP.0000000000001754

Related content

Thoracoscopic versus open oesophagectomy for patients with oesophageal cancer (JCOG1409 MONET): a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial

Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial

Five-Year Outcomes of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy for Locally Advanced Rectal Cancer: Updated Results of the STELLAR Trial

Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial

Elafibranor in primary biliary cholangitis: two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE® phase III trial

Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial

Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial

Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

A randomized, double-blind, phase 3, non-inferiority trial of pradefovir mesylate versus tenofovir disoproxil fumarate in chinese patients with chronic hepatitis B